Article in ACS chemical biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
7 authors.
Kayla NutschDepartment of Chemistry, The Scripps Research Institute, La Jolla, California 92037-1000, United States.
Marissa N TrujilloDepartment of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, Tucson, Arizona 85721-0202, United States.
Lirui SongA Division of Scripps Research, Calibr-Skaggs Institute for Innovative Medicines, La Jolla, California 92037-1000, United States.
Michael A ErbDepartment of Chemistry, The Scripps Research Institute, La Jolla, California 92037-1000, United States.ORCID 0000-0001-9993-3481
Jian Jeffery ChenA Division of Scripps Research, Calibr-Skaggs Institute for Innovative Medicines, La Jolla, California 92037-1000, United States.
James J GalliganDepartment of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, Tucson, Arizona 85721-0202, United States.
Michael J BollongDepartment of Chemistry, The Scripps Research Institute, La Jolla, California 92037-1000, United States.ORCID 0000-0001-9439-1476
Funding
CHEMISTRY-BIOLOGY INTERFACE TRAINING PROGRAMT32GM008804 · NIGMS · UNIVERSITY OF ARIZONA · PI MONTFORT, WILLIAM R. · 2003 to 2023
$3.9M
Targeting crotonyl-lysine chromatin readers to disrupt pathogenic gene expression in leukemiaDP5OD026380 · OD · SCRIPPS RESEARCH INSTITUTE, THE · PI ERB, MICHAEL A · 2018 to 2022
$2.4M
Methods and approaches to expand the pharmacological toolsetR35GM146865 · NIGMS · SCRIPPS RESEARCH INSTITUTE, THE · PI Michael J Bollong · 2022 to 2026
$2.3M
Establishing Glyoxalase 2 as a Viable Target for the Treatment of Disease [Equipment Supplement]R35GM137910 · NIGMS · UNIVERSITY OF ARIZONA · PI GALLIGAN, JAMES J · 2020 to 2024
$2.1M
Glyoxalase 1 and its Role in Metabolic SyndromeR01DK133196 · NIDDK · UNIVERSITY OF ARIZONA · PI James J Galligan · 2023 to 2026
$1.8M
Cancer-specific dependencies within the NuRD chromatin remodeler complex: new targets and chemical toolsR01CA280720 · NCI · SCRIPPS RESEARCH INSTITUTE, THE · PI Michael A Erb · 2024 to 2026
Activation of the YAP-TEAD transcriptional complex drives the growth of several cancer types and is a key resistance mechanism to targeted therapies. Accordingly, a host of pharmacological inhibitors to TEAD family paralogs have been developed, yet little is known as to the resistance mechanisms that might arise against this emerging therapeutic class. Here, we report that genetic augmentation of
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Augmented Acyl-CoA Biosynthesis Promotes Resistance to TEAD Palmitoylation Site Inhibition. · full record | OpenQuestion